Drug Profile
Research programme: retinal disorder therapeutics - Kodiak Sciences
Alternative Names: KSI 201; KSI 401Latest Information Update: 31 May 2022
Price :
$50
*
At a glance
- Originator Oligasis
- Developer Kodiak Sciences
- Class Eye disorder therapies; Immunoconjugates
- Mechanism of Action Angiogenesis inhibitors; Angiotensinogen modulators; Complement system protein inhibitors; Interleukin 6 inhibitors; Vascular endothelial growth factors inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Dry age-related macular degeneration; Glaucoma; Wet age-related macular degeneration
Most Recent Events
- 31 May 2022 Preclinical development is still ongoing for Glaucoma and Dry age-related macular degeneration in USA
- 28 May 2022 No recent reports of development identified for preclinical development in Dry age-related macular degeneration in USA (Parenteral, Injection)
- 26 Apr 2018 Preclinical trials in Glaucoma, Dry age-related macular degeneration, and Wet age-related macular degeneration in USA (Parenteral), prior to April 2018